期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 30, 期 5, 页码 455-462出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0000000000000392
关键词
global health; influenza vaccine; low-income and middle-income countries; maternal and child health; pregnancy
资金
- Centers for Disease Control and Prevention (CDC) [U50 CK000431]
- PATH
- Robert Wood Johnson Foundation
- US National Institutes of Health (NIH)
- Bill & Melinda Gates Foundation (BMGF)
- CDC
- NIH
- BMGF
- WHO
- US Biomedical Advanced Research and Development Authority (BARDA)
Purpose of review In 2018, Gavi, the Vaccine Alliance, is expected to review the strategy of maternal influenza immunization for potential investment in low-income countries. Recent findings Clinical trial data confirm the efficacy of maternal influenza immunization to prevent influenza disease in both mothers and their infants during the first months of life. Trial and observational data indicate no significant adverse events in mothers or newborns. High-quality disease burden data, particularly for seasonal influenza in low-income and middle-income countries, are limited. Thus, the anticipated impact of maternal influenza immunization programs on severe illness is unclear. However, assessments of the public health value of investment in maternal influenza immunization should extend beyond calculations of disease prevention and include broader effects such as improving health systems for antenatal care delivery, preventing inappropriate antibacterial prescribing, building a platform for other vaccines to be used during pregnancy, and strengthening systems to regulate, procure, and distribute influenza vaccines in response to a future pandemic. Summary A global investment in a maternal influenza immunization strategy would prevent influenza disease in pregnant women and their infants. It would also provide additional public health value by strengthening antenatal care systems and improving country pandemic preparedness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据